Judge Sides With Novartis In Dementia Patch Patent Row

Law360, Los Angeles (June 18, 2014, 8:18 PM EDT) -- A Delaware federal judge on Wednesday found that Watson Laboratories Inc. infringed on two of Novartis Pharmaceuticals Corp.’s patents for a patch that treats Alzheimer’s disease, asking the brand-name drugmaker to file a draft of a final judgment in its favor.

U.S. District Judge Richard G. Andrews ruled that Novartis effectively showed that an abbreviated new drug application filed by Watson ripped off some of the functions and materials of its dementia treatment Exelon, a patch that allows patients to absorb drugs through the skin, according to the decision.

“Novartis proved that Watson's ANDA products infringe by a preponderance of the...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS